Arbutus to Participate in June Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 7/25/2026

1. INTC
2. DECK
3. META
4. AMD
5. INFY

6. SPY
7. TMUS
8. UNP
9. GOOGL
10. RNG

Get Alerts ABUS Hot Sheet

Price: $4.38 -2.01%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

WARMINSTER, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in the following upcoming investor conferences taking place in New York:

Jefferies Healthcare Conference (June 8 - 10, 2022)

Fireside Chat: 3:00 pm ET on Thursday, June 9, 2022
Presenters: Michael McElhaugh, Chief Business Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer

JMP Securities Life Sciences Conference (June 15 - 16, 2022)

Fireside Chat: 9:00 am ET on Wednesday, June 15, 2022
Presenters: Michael McElhaugh, Chief Business Officer; Dr. Michael Sofia; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer

Live webcasts of the fireside chats can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com. An archived replay of the webcast will be available on the Arbutus website after the event.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. In HBV, we are developing a RNAi therapeutic, oral capsid inhibitor, oral PD-L1 inhibitor, and oral RNA destabilizer that we intend to combine to provide a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. It is currently being evaluated in multiple phase 2 clinical trials. We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2). In addition, we are exploring oncology applications for our internal PD-L1 portfolio. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

William H. CollierPresident and CEO Phone: 267-469-0914Email: [email protected]

Lisa M. CaperelliVice President, Investor RelationsPhone: 215-206-1822Email: [email protected]